



We have fifteen minutes!

- 1. Why screen for psychological distress?
- 2. What process are we using?
- 3. What do we think we know from our first 5,198 records?

Why screen for psychological distress?

- 1. The diagnosis, or the fear of a diagnosis, of a life-threatening illness creates immediate distress.
- 2. Everyone experiences a shift in his or her level of comfort.
- Approximately one-third of all cancer patients experience prolonged highdistress.

Why screen for psychological distress?

- 4. Because we cannot see everyone.
- 5. Not everyone needs to be seen.
- 6. We cannot rely on the old adage of "build it and they will come".
- 7. To know that people are in distress, and not at least attempt to identify those who are most in need, would be professionally irresponsible.

And if I may, while on this topic ...

- Screening for psychological distress needs to be viewed in the same way as we would view screening for . . . diabetes, say.
- By that, I mean, that while it would not be appropriate, generally, for me to screen for diabetes, although I am sure I could, I ought not to for it is outside the scope of my practice.

And furthermore, if you will allow me ...

- Given what we know about the existence of psychological distress in this population:
 - we <u>must</u> assess for those <u>most in need</u> of having their unmet needs met;
 - 2. we need to think of this as being as routine a "best practice" as is sending someone up to the lab; and,
 - we need to think seriously about how that information (the result) is shared – by whom and to whom.

And what do I mean?

- Any screening tool is simply that . . . a tool.
- Ideally, certain tools are only used by certain people.
- Although the guidelines for using a screening tool are generally just that (guidelines), screening implies that you are going to do something appropriate in the event that you identify "a case".

Ideally ...

- the screening tool is but one bit of evidence used by a program team; and
- the team decides perhaps in consultation with the patient – "to whom that bit of information goes" and who it is that will sit with the patient and pursue the matter.

What tool might you use?

- It think it is fair to say that it is not so important what tool you use, but that you do use one; and,
- similarly, it may not be so important when you use that tool, but, again, that you at least do something!

What tool might you use?

- And it is probably important that it be recognized as a <u>screening tool</u> and not a <u>diagnostic tool</u>.
- Why? Two reasons:
 - 1. Diagnostic tools come with labels and biases and assumptions, and stigma . . . and are lengthy and subtle and occasionally deceptive.
 - Diagnostic tools reduce the importance of the person-to-person contact that is essential in initiating the kind of outreach and connection I would argue as being a cornerstone to what we need to be doing.

What tool might you use?

- Remember, a screening tool is merely a "thermometer".
- The gentleman has an elevated core temperature, or so it would appear . . .
 - 1. Could be he has a raging infection.
 - 2. Could be he fell asleep in the sauna!

Requirements of a screening tool

- 1. It must be easily administered.
- 2. It must be easily scored.
- 3. It must be easily interpreted.
- 4. It must be valid and reliable.

The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983)


- is an easily administered self-report measure designed specifically for persons with a physical illness;
- 2. is made up of 14 items, each consisting of a four-point Likert scale ranging from zero to three, with varying response categories, that applies to the previous week;

The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983)

- 3. usually takes about three to five minutes to complete and is very easy to score;
- 4. is divided into two subscales, with:
 - a. seven items pertaining to symptoms associated with anxiety, and
 - b. seven items pertaining to symptoms associated with depression;

The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983)

- appears to be a suitable instrument for oncology settings (Razavi, Delvaux, Farvacques, & Robaye, 1990);
- contains no somatic items that may confound results by elevating the scores of cancer patients; and
- 7. has good reliability and validity in physically ill patients.



Scoring the HADS For each subscale, a score ranging from 0 – 21 (7 x 0 = 0; 7 x 3 = 21) is calculated: scores less than eight on either of the two subscales are deemed to be "non-cases"; scores of eight, nine, or ten are rated as "borderline"; and

 scores of eleven or more on either of the two subscales is indicative of the "probable" presence of psychological distress.

Scoring the HADS

4. However, if a "borderline" score (i.e., eight, nine, or ten) is found on both subscales at the same time, the individual is considered "at risk" for psychological distress.

What process are we using?

- 1. All new Cancer Centre patients are asked to complete the HADS as part of the New Patient Package.
- 2. Patients complete the HADS while sitting in the waiting room, prior to seeing anyone.
- 3. The receptionists place the completed HADS in the Supportive Care mail slot.

What process are we using?

- 4. Twice per day, Alan picks up the completed HADS, scores them, and, if required (i.e., if "high"):
 - a. makes photocopies of the "high-HADS";
 - b. prints and attaches "OPIS face sheets" to the "high-HADS"; and
 - c. brings the "high-HADS packages" to our weekly clinical meeting.

What process are we using?

- 5. At the weekly clinical meeting:
 - a. we go through each of the "cases";
 - b. the team decides how to proceed; and
 - c. phone calls are placed within 72 hours.
- 6. Or, if the "high-HADS" are so high they need to be acted on sooner, Alan takes them directly to Lori, in which case she will stop me and we will jointly triage, and not wait for the Thursday morning meeting.

And what then?

- A file is opened if the person is going to be seen by one of the counsellors in Supportive Care.
- 8. A file is not opened if "services are declined" (i.e., "thanks, but no-thanks").
- 9. Regardless, the data are captured and all HADS forms are kept in a common file.

Some HADS data


- We began collecting HADS data on October 10, 2000; as of May 18, 2007 we have collected HADS data on 5,198 cancer patients.
- Over the past six-plus years we have collected "completely completed" HADS from 4,505 patients (RR = 87%).
- If we include the "incomplete" HADS during that same time frame, our N = 4,800 (RR = 92%).




- Looking at that larger number of patients (i.e., N = 4,800), the average (mean) scores are as follows:
 - Anxiety Subscale = 6.73 / 21 (SD = 4.52)
 - Depression Subscale = 4.39 / 21 (SD = 3.94)
 - Overall Distress Score = 11.08 / 42 (SD = 7.29)
- And 1,237 of these patients (26%) have scored above "threshold".



- What if, after all this trouble, nobody bothered to take us up on our invitation?
- Well, of these (the 26%):
 - 1. we were successful in contacting 952 patients (78%) by phone; and, of these . . .
 - 2. 850 patients (89%) made an appointment when called and asked whether they would like an appointment with one of the Counsellors in Supportive Care.





Primary Site	Frequency (N)	Percent (%)	Anxiety Subscale	Depression Subscale	Overall Distress
Breast	1,125	23.3	7.41	3.69	11.09
Prostate	855	17.8	5.62	3.61	9.22
Colorectal	603	12.5	6.35	4.53	10.64
Lung	552	11.4	7.76	6.27	14.03
Skin	173	3.6	5.38	3.50	8.88
NHL	170	3.6	6.85	4.63	11.48
Bladder	106	2.2	6.19	4.76	10.95
Kidney	100	2.1	6.06	3.59	9.65
TOTAL	3,684	76.6	6.68	4.26	10.89

		ntage above threshold					
Males				Females			
Primary Site	Frequency (N)	% Above Threshold		Primary Site	Frequency (N)	% Above Threshold	
Breast	5	40.0		Breast	1,120	26.3	
Prostate	855	15.9		Prostate	-	-	
Colorectal	357	19.0		Colorectal	246	27.6	
Lung	310	38.1		Lung	242	43.0	
Skin	101	15.8		Skin	72	22.2	
NHL	85	24.7		NHL	85	34.1	
Bladder	70	25.7		Bladder	36	19.4	
Kidney	62	16.1		Kidney	38	28.9	
TOTAL	1.845	21.1		TOTAL	1,839	28.8	

References

- Ballenger JC, Davidson JRT, Lecrohier Y, Nutt DJ, Jones RD, Berard RMF. 2001. Consensus statement on depression, anxiety, and oncology. J Clin Psychol 62: 64-7.
 Barg FK, Cooley M, Pasacreta J, Senay B, McCockle R. 1994. Development of a self-administered psychosocial cancer screening tool. Cancer Prinz 149, 282-396.
 Biglinda J, Dahl AA, Hang TT, Neckelmunn D. 2002. The validity of the Hospital Anxiety and Depression Scale: an updated literature review. J Psychoma Res 52(2): 66-77.
 Backlerg J, Pennan D, Holland JC. 1994. Depression in hospitalized cancer patients. Psychocom Res 55: 403-9.
 Carroll JT, Kathol RD. 2003. Cancer discusses areaining active sciencing for depression and anxiety in cancer patients using the Hospital Nativity and Depression. Scale. Con Hosp Psychiatry 15: 60-78.
 Carroll JT, Kathol RG, Noyes R, Wald TG, Channo GH. 1993. Screening for depression and anxiety in cancer patients using the Hospital Anxiety and Depression. Scale. Con Hosp Psychiatry 15: 60-79.
 Carroll JT, Kathol RG, Noyes R, Wald TG, Channo GH. 1995. Screening for depression. cognitive dysfunction and age in Charles K. Scillster, Morek 2005. Models EA. 1996;Abir 216: 60-79.
 Carroll SE, Scillster S, Montesaron D, Molde EA. 1996;Psichari 715: 60-79.
 Carroll SE, Kathol M, McBath C. 1996. Cancer patients and their physicians in their preception of psychological symptom. Psychosometra 17: 197-201.
 Dergasis LR, Abadel M, McBath C. 1976. Cancer patients and their physicians in their preception of psychological symptom. Psychosometra 17: 197-201.

- symptom. Psychonomatrix 17: 197-201. Decogatis LB, Medisaton N. 1983. The Brief Symptom Inventory: an introductory report. Psychol Med 13: 595-605. Decogatis LB, Morow GR, Ferting J, Pennan D, Paustsky S, Schmale AM, Henrichs M, Camicke CL Jr. 1983. The prevalence of psychiatric disorders among cancer patients. JAMA 249: 751-7. Decogatis LB, Spencer PM. 1984. Psychometric issues in the psychological assessment of the cancer patient. Cancer 53: 2228-2232.
- 1223-6242. Faber JM, Weinerman BH, Kuppers JA. 1984. Psychosocial distenses of neodology patients. J Psychosoc Oscol 2: 100-18. Faber JM. 2003. Supportive Care. Robalancing efforts: In Strengthening the Quality of Care Services in Ontario, Sullivan T, Evans W, Angen H, Hadson A (eds.) Ottawa: CHA beness.
 Fitch ML, McGrath PN. 2003. The needs of family members of patients receiving radioactive iodine. Can Oncol Nurs J 13(4): 220-31.

References (continued)

- Fitch MI, 2003. Psychosocial management of patients with recurrent ovarian cancer: treating the whole patient to improve quality of life. Somin Oncol Nurs 1903 Suppl 11: 40-53.
 Fitch MI, Gray RE, Megowan T, Brunskill I, Steggles S, Sellick S, Berjak A, McLeese D. 2005. Travelling for radiation cancer treatment patient subication. Con Oreol Nurs 1902; 10:71-90.
 Gravit M, Gray RE, Megowan T, Brunskill I, Steggles S, Sellick S, Berjak A, McLeese D. 2005. Travelling for radiation cancer treatment patient subication. Con Oreol Nurs 1962; 10:71-90.
 Gravit M, Brasten D, Stegle J, Fitch MJ. 2004. A consultation with Canadian rural women with breast cancer. Realist from a population-based survey. Support Core Cancer 108); 657:52.
 Gray RE, Lanese F, Mantore J, Gould J, Fitch MJ. 2004. A consultation with Canadian rural women with breast cancer. Health Expect 7(1): 40-50.
 Hall A, A'Hen R, Fallowfield L. 1999. Are we using papopriate self-report questionnaires for detecting anxiety and depression in women with andy breast cancer? Eur J Cancer 38: 79-85.
 Holland JC: 1989. Anxiety and cancers. The patient and the family. J Clin Psychiary 59: 20-25.
 Hobston T, Maguire P, Selby P, Priestman T, Wallace L. 1994. Screening for anxiety and depression in acacer patients: The effects of disease and treatment. Eur J Clancer 38: 757-858.
 Hobston T, Maguire P, Selby P, Priestman T, Wallace L. 1994. Screening for anxiety and Depression scale as a screening tool inpatients with anore diseased cancer. J Fan J Maynor Manage 22: 1990.
 Loyd-Milliams M, Friedman T, Rudd N. 2001. An analysis of the validity of the Hospital Anxiety and Depression scale as a screening tool inpatients with anore diseased cancer. J Fan J Maynor Manage 22: 1990.
 Layd-Milliams M, Erioffond Cancer (J Millow Millow Manage 22: 1991.
 Layd-Milliams M, Erioffond Cancer (J Millow J, Pole J Millow J Millow Manage 22: 1991.
 Hospital Pitto J Millow M, 2001. An analysis of the validity of th Lynch ME (1995; The assessment and prevalence of affective disorders in advanced cancer. J. Palliul Care 11(1): 10-18. Magaire P. 1985; Marriser to psychological cance of the dying. *Br Med* **179**: 1171-1173. National Comprehensive Cancer Network (NCCN), 2005. Clinical Practice Gaidelines in Onology – Version 1.2005. http://www.acc.org/profosional/science/pdf/distres.pdf National Research Corporation Inc. (2005). Antebiatory Onoclogy Patient Experience Survey. Contact: <u>Marrial Control</u> (March Control), Predicting anxiety and depression among cancer patients: a clinical Nodink C. Bargel G. Climative B, Scieder D. 2001. Predicting anxiety and depression among cancer patients: a clinical Nodink C. Bargel G. Climative B, Scieder D. 2001. Predicting anxiety and depression among cancer patients: a clinical react in patients. *Br J Psychiatry* **156**: 79-83.

References (continued)

Razavi D, Delvaux N, Bredart A, Paesmans M, Debascher L, Bron D, Stryckmans P. 1992. Screening for psychiatric disorders in a lymphoma out-patient population. *Eur J Cancer* 28A(11): 1869-72.Rodgers J, Martin CR, Morse RC, Kendell K, Verrill M. 2005. An investigation into the psychometric properties of the Hospital Anxiety and Depression Scale in patients with heast cancer. *Health Quil Life Outcome* 3: 41.

- erties of the

- Redgers J, Martin CR, Morse RC, Kendell K, Verrill M. 2005. An investigation into the psychometric properties of the Hospital Ancetty and Depression Scale in patients with breast cancer. Health Qual Lfe durones 34:1.
 Roth A, Kornbith AB, Badel-Copel L, Peabody E, Scher HI, Holland JC. 1998. Rapid screening for psychological distress in men with product carcinoma. *Cancer* 28(10): 1904-1908.
 Schulberg JC, Banss BJ. 1988. Mental disorders in primary care: Epidemiologic, diagnotic, and treatment research directions. *Canc Impo Psychiatry Dis 7:847*.
 Schuberg JC, Banss BJ. 1988. Mental disorders in primary care: Epidemiologic, diagnotic, and treatment research directions. *Cancer Datop Psychiatry Dis 7:847*.
 Schuber JD, Bildow M, Brown JM *et al.* 1967. Diagnosing depression in medical impatients. *Ann Intern Med* 67: 605-707.
 Schuber JD, Bildow M, Brown JM *et al.* 1967. Diagnosing depression concollegy compatients: prevalence and severity as measured with the Brief Symptom Inventory. *Psychosomatics* 28(10): 537-8.
 Weisman AD. 1979. Fardy diagnosis of vulnerability in cancer patients for psychologist JL filts vol. *Action Schuber* 2019; 537-8.
 Weisman AD. 1979. Fardy diagnosis of vulnerability in cancer spatients. *Ann J Med Sci* 271: 187-196.
 Weisman AD. 1976. Tark diagnosis of vulnerability in cancer spatients. *Ann J Med Sci* 271: 187-196.
 Weisman AD. 1976. The cistential pight in cancer: asplintcance of the first 100 days. Psychiatry 11: 1-15.
 Weisman AD. 1976. The cistential pight in cancer: Gatopic Psychiatry 11: 187-196.
 Weisman AD. 1976. The cistential pight in cancer: spatificance of the first 100 days. Psychiatry 41: 1-15.
 Weisman AD. 1976. The cistential pight in cancer: Gatopic Psychiatry 11: 187-196.
 Weisman AD. 1976. The cistential pight in cancer: asplittense for the first 100 days. Psychiatry 41: 1-15.
 Weisman AD. 1976. The cistential pight in cancer: Gatopic Psychiatry 11: 187-196.
 Weisman

psychosocial screening instrument for use with cancer patients. *Psychosomatics* 42(3): 241-6. nond AS, Snaith RP. 1983. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand* 67: 361-370.

Dr. Scott M. Sellick is an Associate Research Scientist in Psychosocial Oncology and Director of Supportive Care at the Thunder **Bay Regional Health Sciences Centre in** Thunder Bay, Ontario, Canada.

Alan D. Edwardson is a Clinical Researcher with Supportive Care.



For more information please contact: Dr. Scott M. Sellick, Director, Supportive Care, Thunder Bay Regional Health Sciences Centre, 980 Oliver Road – Room 3133, Thunder Bay, Ontario, Canada P7B 6V4 phone 807-684-7310; fax 807-684-5805; email sellicks@th.net.

Psychological distress among cancer patients: Screening for triage and referral